#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS

Aktualizované odporúčania ESC/EAS 2025: dyslipidémia v centre modernej kardiovaskulárnej prevencie

3. 1. 2026 Source: Athero Review | 1/2026

The position of combined treatment in the context of updated ESC/EAS recommendations for the management of dyslipidemias

3. 1. 2026 Source: Athero Review | 1/2026

Bempedoic acid in the updated recommendations for the management of dyslipidemias ESC/EAS 2025

3. 1. 2026 Source: Athero Review | 1/2026

Target LDL cholesterol levels in high-risk populations in Slovakia: a retrospective study

3. 1. 2026 Source: Athero Review | 1/2026

Metabolic dysfunction associated steatotic liver disease: from pathogenesis to clinical cardio-metabolic implications

3. 1. 2026 Source: Athero Review | 1/2026

Current view on lipoprotein(a): diagnosis and treatment

3. 1. 2026 Source: Athero Review | 1/2026

Atherosclerosis risk and CV risk reduction in GLP1-RA treated patients

3. 1. 2026 Source: Athero Review | 1/2026

Patients with HIV –⁠ management of dyslipidemia, arterial hypertension, and cardiovascular risk: new challenges in the era of effective antiretroviral therapy

3. 1. 2026 Source: Athero Review | 1/2026

Prevention of anthracycline-induced cardiotoxicity as a new potential indication for statins?

3. 1. 2026 Source: Athero Review | 1/2026

Artificial intelligence in cardiovascular risk management: from digital medical history to personalized therapy

3. 1. 2026 Source: Athero Review | 1/2026

The impact of ultra-processed foods on dyslipidemia

3. 1. 2026 Source: Athero Review | 1/2026

Research on remarkable articles from international literature

3. 1. 2026 Source: Athero Review | 1/2026

Rok 2025 –⁠ rok významných kardiologických studií

3. 1. 2026 Source: Athero Review | 1/2026
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#